Rekah Pharmaceutical Industry Ltd Total Liabilities
Rekah Pharmaceutical Industry Ltd total liabilities. Based on the latest financial reports, Rekah Pharmaceutical Industry Ltd (REKA) has total liabilities worth ILA281.29 Million ILA (≈ $754.13K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Rekah Pharmaceutical Industry Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Rekah Pharmaceutical Industry Ltd (2004–2025)
Total liabilities of Rekah Pharmaceutical Industry Ltd from 2004 to 2025. This chart illustrates how Rekah Pharmaceutical Industry Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Rekah Pharmaceutical Industry Ltd (REKA) long-term investment share to see how much of total assets are deployed in long-term investments.
Rekah Pharmaceutical Industry Ltd Competitors by Total Liabilities
The table below lists competitors of Rekah Pharmaceutical Industry Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gencurix Inc
KQ:229000
|
Korea | ₩18.57 Billion |
|
K Way Information
TWO:5201
|
Taiwan | NT$264.47 Million |
|
TINYBUILD REGSCAT3 DL-001
F:8Z3
|
Germany | €11.50 Million |
|
Fridenson
TA:FRDN
|
Israel | ILA185.56 Million |
|
Dong A Eltek Co. Ltd
KQ:088130
|
Korea | ₩390.43 Billion |
|
Radana Bhaskara Finance Tbk
JK:HDFA
|
Indonesia | Rp3.07 Trillion |
|
Enapter AG
F:H2O
|
Germany | €89.32 Million |
|
Globrands Group Ltd
TA:GLRS
|
Israel | ILA476.20 Million |
Liability Composition Analysis (2004–2025)
This chart breaks down Rekah Pharmaceutical Industry Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see REKA asset base.
Liquidity & Leverage Metrics
Rekah Pharmaceutical Industry Ltd Total Liabilities Ratios Explained
Rekah Pharmaceutical Industry Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rekah Pharmaceutical Industry Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rekah Pharmaceutical Industry Ltd (2004–2025)
The table below shows the annual total liabilities of Rekah Pharmaceutical Industry Ltd from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ILA279.47 Million ≈ $749.25K |
-2.02% |
| 2024-12-31 | ILA285.24 Million ≈ $764.73K |
-13.34% |
| 2023-12-31 | ILA329.14 Million ≈ $882.40K |
+14.95% |
| 2022-12-31 | ILA286.34 Million ≈ $767.66K |
+8.45% |
| 2021-12-31 | ILA264.02 Million ≈ $707.84K |
+3.91% |
| 2020-12-31 | ILA254.10 Million ≈ $681.23K |
+19.92% |
| 2019-12-31 | ILA211.89 Million ≈ $568.08K |
+41.62% |
| 2018-12-31 | ILA149.62 Million ≈ $401.13K |
-0.47% |
| 2017-12-31 | ILA150.33 Million ≈ $403.02K |
-30.68% |
| 2016-12-31 | ILA216.86 Million ≈ $581.40K |
+8.34% |
| 2015-12-31 | ILA200.17 Million ≈ $536.64K |
-14.11% |
| 2014-12-31 | ILA233.05 Million ≈ $624.81K |
+4.21% |
| 2013-12-31 | ILA223.65 Million ≈ $599.59K |
-1.43% |
| 2012-12-31 | ILA226.90 Million ≈ $608.32K |
+1.76% |
| 2011-12-31 | ILA222.98 Million ≈ $597.81K |
-0.54% |
| 2010-12-31 | ILA224.18 Million ≈ $601.03K |
+4.64% |
| 2009-12-31 | ILA214.25 Million ≈ $574.39K |
-7.60% |
| 2008-12-31 | ILA231.87 Million ≈ $621.64K |
-0.85% |
| 2007-12-31 | ILA233.86 Million ≈ $626.98K |
-0.48% |
| 2006-12-31 | ILA234.99 Million ≈ $630.01K |
+12.90% |
| 2005-12-31 | ILA208.15 Million ≈ $558.04K |
+35.89% |
| 2004-12-31 | ILA153.18 Million ≈ $410.66K |
-- |
About Rekah Pharmaceutical Industry Ltd
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of pharmaceuticals, cosmetics, vitamins and nutritional supplements, and medical devices in Israel. The company offers steroids, antibiotics, and ophthalmic products, as well as dermo-cosmetics products. Its portfolio of products comprise Rx and OTC drugs, and medical devices used in various therapeut… Read more